References

Alonso, A., and G. Molenberghs. 2008. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Statistical Methods in Medical Research 17(5):497–504.

Antman, E. M., M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, J. S. Hochman, H. M. Krumholz, G. A. Lamas, C. J. Mullany, D. L. Pearle, M. A. Sloan, S. C. Smith, Jr., D. T. Anbe, F. G. Kushner, J. P. Ornato, A. K. Jacobs, C. D. Adams, J. L. Anderson, C. E. Buller, M. A. Creager, S. M. Ettinger, J. L. Halperin, S. A. Hunt, B. W. Lytle, R. Nishimura, R. L. Page, B. Riegel, L. G. Tarkington, and C. W. Yancy. 2008. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 51(2):210–247.

Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes. 2005. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278.

Bardy, G. H., K. L. Lee, D. B. Mark, J. E. Poole, D. L. Packer, R. Boineau, M. Domanski, C. Troutman, J. Anderson, G. Johnson, S. E. McNulty, N. Clapp-Channing, L. D. Davidson-Ray, E. S. Fraulo, D. P. Fishbein, R. M. Luceri, and J. H. Ip. 2005. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine 352(3):225–237.

Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, C. L. Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall, and B. Brewer. 2007. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 357(21):2109–2122.

Besarab, A., W. K. Bolton, J. K. Browne, J. C. Egrie, A. R. Nissenson, D. M. Okamoto, S. J. Schwab, and D. A. Goodkin. 1998. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 339(9):584–590.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 99
References Alonso, A., and G. Molenberghs. 2008. Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Statistical Methods in Medi- cal Research 17(5):497–504. Antman, E. M., M. Hand, P. W. Armstrong, E. R. Bates, L. A. Green, L. K. Halasyamani, J. S. Hochman, H. M. Krumholz, G. A. Lamas, C. J. Mullany, D. L. Pearle, M. A. Sloan, S. C. Smith, Jr., D. T. Anbe, F. G. Kushner, J. P. Ornato, A. K. Jacobs, C. D. Adams, J. L. Anderson, C. E. Buller, M. A. Creager, S. M. Ettinger, J. L. Halperin, S. A. Hunt, B. W. Lytle, R. Nishimura, R. L. Page, B. Riegel, L. G. Tarkington, and C. W. Yancy. 2008. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology 51(2):210–247. Baigent, C., A. Keech, P. M. Kearney, L. Blackwell, G. Buck, C. Pollicino, A. Kirby, T. Sourjina, R. Peto, R. Collins, and R. Simes. 2005. Efficacy and safety of cholesterol-lowering treat- ment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493):1267–1278. Bardy, G. H., K. L. Lee, D. B. Mark, J. E. Poole, D. L. Packer, R. Boineau, M. Domanski, C. Troutman, J. Anderson, G. Johnson, S. E. McNulty, N. Clapp-Channing, L. D. Davidson-Ray, E. S. Fraulo, D. P. Fishbein, R. M. Luceri, and J. H. Ip. 2005. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. New England Journal of Medicine 352(3):225–237. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez- Sendon, L. Mosca, J. C. Tardif, D. D. Waters, C. L. Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall, and B. Brewer. 2007. Effects of torcetrapib in patients at high risk for coronary events. New England Journal of Medicine 357(21):2109–2122. Besarab, A., W. K. Bolton, J. K. Browne, J. C. Egrie, A. R. Nissenson, D. M. Okamoto, S. J. Schwab, and D. A. Goodkin. 1998. The effects of normal as compared with low hemato - crit values in patients with cardiac disease who are receiving hemodialysis and epoetin. New England Journal of Medicine 339(9):584–590. 

OCR for page 99
100 BIOMARKER AND SURROGATE ENDPOINT EVALUATION Bigger, Jr., J. T. 1986. Long-term continuous electrocardiographic recordings and electro - physiologic testing to select patients with ventricular arrhythmias for drug trials and to determine antiarrhythmic drug efficacy. American Journal of Cardiology 58(5):58C–65C. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate endpoints: Pre - ferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 69(3):89–95. Califf, R. M. 2006. Clinical trials bureaucracy: Unintended consequences of well-intentioned policy. Clinical Trials 3(6):496–502. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. 1989. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppres - sion after myocardial infarction. New England Journal of Medicine 321(6):406–412. Castelli, W. P. 1988. Cholesterol and lipids in the risk of coronary artery disease—The Fram - ingham Heart Study. Canadian Journal of Cardiology 4(Suppl A):5A–10A. CFSAN (Center for Food Safety and Applied Nutrition). 2009. Guidance for industry: Evidence- based review system for the scientific evaluation of health claims. http://www.cfsan.fda. gov/~dms/hclmgui6.html (accessed February 25, 2009). Cook, N. R., J. E. Buring, and P. M. Ridker. 2006. The effect of including C-reactive pro - tein in cardiovascular risk prediction models for women. Annals of Internal Medicine 145(1):21–29. de Lorgeril, M., P. Salen, J. L. Martin, I. Monjaud, J. Delaye, and N. Mamelle. 1999. Medi - terranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon Diet Heart Study. Circulation 99(6):779–785. Dieterle, F., F. Sistare, F. Goodsaid, M. Papaluca, J. S. Ozer, C. P. Webb, W. Baer, A. Senagore, M. J. Schipper, J. Vonderscher, S. Sultana, D. L. Gerhold, J. A. Phillips, G. Maurer, K. Carl, D. Laurie, E. Harpur, M. Sonee, D. Ennulat, D. Holder, D. Andrews-Cleavenger, Y. Z. Gu, K. L. Thompson, P. L. Goering, J. M. Vidal, E. Abadie, R. Maciulaitis, D. Jacobson-Kram, A. F. Defelice, E. A. Hausner, M. Blank, A. Thompson, P. Harlow, D. Throckmorton, S. xiao, N. xu, W. Taylor, S. Vamvakas, B. Flamion, B. S. Lima, P. Kasper, M. Pasanen, K. Prasad, S. Troth, D. Bounous, D. Robinson-Gravatt, G. Betton, M. A. Davis, J. Akunda, J. E. McDuffie, L. Suter, L. Obert, M. Guffroy, M. Pinches, S. Jayadev, E. A. Blomme, S. A. Beushausen, V. G. Barlow, N. Collins, J. Waring, D. Honor, S. Snook, J. Lee, P. Rossi, E. Walker, and W. Mattes. 2010. Renal biomarker qualification submission: A dialog between the FDA-EMEA and Predictive Safety Test - ing Consortium. Nature Biotechnology 28(5):455–462. Dluhy, R. G., and G. T. McMahon. 2008. Intensive glycemic control in the ACCORD and ADVANCE trials. New England Journal of Medicine 358(24):2630–2633. Echt, D. S., P. R. Liebson, L. B. Mitchell, R. W. Peters, D. Obias-Manno, A. H. Barker, D. Arensberg, A. Baker, L. Friedman, H. L. Greene, M. L. Huther, D. W. Richardson, and CAST Investigators. 1991. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine 324(12):781–788. FDA (Food and Drug Administration). 2009. Summary of qualified health claims subject to enforcement discretion. http://www.fda.gov/Food/LabelingNutrition/LabelClaims/ QualifiedHealthClaims/ucm073992.htm#gtea (accessed October 12, 2010). Fleming, T. R. 2005. Surrogate endpoints and FDA’s accelerated approval process. Health Affairs (Millwood) 24(1):67–78. Fleming, T. R., and D. L. DeMets. 1996. Surrogate end points in clinical trials: Are we being misled? Annals of Internal Medicine 125(7):605–613.

OCR for page 99
101 REFERENCES Gallin, J. I., H. L. Malech, D. A. Melnik, R. S. Weening, D. Roos, H. Wendt, R. C. Woodman, J. T. Curnutte, R. A. Seger, T. Muhlebach, J. P. Bourquin, R. A. Axtell, L. A. Boxer, C. L. Pierson, D. C. Anderson, W. T. Shearer, H. M. Rosenblatt, J. C. Torkildson, R. L. Baehner, T. D. Coates, K. Belani, P. G. Quie, N. H. Valerius, C. Koch, F. K. Pedersen, H. R. Hill, A. Shigeoka, S. H. Fischer, H. Rosen, H. D. Ochs, T. R. Fleming, C. Cunningham Rundles, A. Hyatt, H. Evrard, C. Nathan, C. Farber, R. A. B. Ezekowitz, A. E. Izu, S. M. Kramer, and H. S. Jaffe. 1991. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 324(8):509–516. GAO (Government Accountability Office). 2000. Food safety: Improvements needed in overseeing the safety of dietary supplements and “functional foods.” Washington, DC: GAO. Gobburu, J. V. 2009. Biomarkers in clinical drug development. Clinical Pharmacology and Therapeutics 86(1):26–27. Gordon, D. J. 1994. Cholesterol lowering and total mortality. In Contemporary issues in cholestorol lowering: Clinical and population aspects, edited by B. M. Rifkind. New York: Marcel Dekker. Gordon, T., W. P. Castelli, M. C. Hjortland, W. B. Kannel, and T. R. Dawber. 1977. High- density lipoprotein as a protective factor against coronary heart disease: The Framing - ham Study. American Journal of Medicine 62(5):707–714. HHS (Department of Health and Human Services). 2005. Dietary Guidelines for Americans. http://www.health.gov/dietaryguidelines/dga2005/document/pdf/DGA2005.pd f (accessed December 15, 2010). Hochman, J. S., G. A. Lamas, C. E. Buller, V. Dzavik, H. R. Reynolds, S. J. Abramsky, S. Forman, W. Ruzyllo, A. P. Maggioni, H. White, Z. Sadowski, A. C. Carvalho, J. M. Rankin, J. P. Renkin, P. G. Steg, A. M. Mascette, G. Sopko, M. E. Pfisterer, J. Leor, V. Fridrich, D. B. Mark, and G. L. Knatterud. 2006. Coronary intervention for persistent occlusion after myocardial infarction. New England Journal of Medicine 355(23):2395–2407. IOM (Institute of Medicine). 2006. Dietary reference intakes: The essential guide to nutrient re- quirements. Washington, DC: The National Academies Press. IOM. 2007a. Cancer biomarkers: The promises and challenges of improving detection and treatment . Washington, DC: The National Academies Press. IOM. 2007b. The future of drug safety: Promoting and protecting the health of the public . Washing- ton, DC: The National Academies Press. IOM. 2010. Evaluation of biomarkers and surrogate endpoints in chronic disease. Washington, DC: The National Academies Press. Lathia, C. D., D. Amakye, W. Dai, C. Girman, S. Madani, J. Mayne, P. MacCarthy, P. Pertel, L. Seman, A. Stoch, P. Tarantino, C. Webster, S. Williams, and J. A. Wagner. 2009. The value, qualification, and regulatory use of surrogate end points in drug development. Clinical Pharmacology and Therapeutics 86(1):32–43. Lewis, M. M. 2003. Moneyball: The art of winning an unfair game. New York: W.W. Norton. Mauri, L., E. J. Orav, and R. E. Kuntz. 2005. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 111(25):3435–3442. Mukharji, J., R. E. Rude, W. K. Poole, N. Gustafson, L. J. Thomas, Jr., H. W. Strauss, A. S. Jaffe, J. E. Muller, R. Roberts, D. S. Raabe, C. H. Croft, E. Passamani, E. Braunwald, J. T. Willerson, and MILIS Study Group. 1984. Risk factors for sudden death after acute myocardial infarction: Two-year follow-up. American Journal of Cardiology 54(1):31–36. Prentice, R. L. 1989. Surrogate endpoints in clinical trials: Definition and operational criteria. Statistics in Medicine 8(4):431–440. Robinson, J. G., and N. J. Stone. 2006. Identifying patients for aggressive cholesterol lower- ing: The risk curve concept. American Journal of Cardiology 98(10):1405–1408.

OCR for page 99
102 BIOMARKER AND SURROGATE ENDPOINT EVALUATION Ruberman, W., E. Weinblatt, J. D. Goldberg, C. W. Frank, and S. Shapiro. 1977. Ventricular premature beats and mortality after myocardial infarction. New England Journal of Medicine 297(14):750–757. Schneeman, B. 2007. FDA’s review of scientific evidence for health claims. Journal of Nutri- tion 137(2):493–494. Seshadri, S., A. L. Fitzpatrick, M. A. Ikram, A. L. DeStefano, V. Gudnason, M. Boada, J. C. Bis, A. V. Smith, M. M. Carassquillo, J. C. Lambert, D. Harold, E. M. Schrijvers, R. Ramirez- Lorca, S. Debette, W. T. Longstreth, Jr., A. C. Janssens, V. S. Pankratz, J. F. Dartigues, P. Hollingworth, T. Aspelund, I. Hernandez, A. Beiser, L. H. Kuller, P. J. Koudstaal, D. W. Dickson, C. Tzourio, R. Abraham, C. Antunez, Y. Du, J. I. Rotter, Y. S. Aulchenko, T. B. Harris, R. C. Petersen, C. Berr, M. J. Owen, J. Lopez-Arrieta, B. N. Varadarajan, J. T. Becker, F. Rivadeneira, M. A. Nalls, N. R. Graff-Radford, D. Campion, S. Auerbach, K. Rice, A. Hofman, P. V. Jonsson, H. Schmidt, M. Lathrop, T. H. Mosley, R. Au, B. M. Psaty, A. G. Uitterlinden, L. A. Farrer, T. Lumley, A. Ruiz, J. Williams, P. Amouyel, S. G. Younkin, P. A. Wolf, L. J. Launer, O. L. Lopez, C. M. van Duijn, and M. M. Breteler. 2010. Genome-wide analysis of genetic loci associated with Alzheimer disease. Journal of the American Medical Association 303(18):1832–1840. Staessen, J. A., J. G. Wang, and L. Thijs. 2003. Cardiovascular prevention and blood pressure reduction: A quantitative overview updated until 1 March 2003. Journal of Hypertension 21(6):1055–1076. Torpy, J. M., C. Lynm, and R. M. Glass. 2007. JAMA patient page. Implantable cardioverter- defibrillators. Journal of the American Medical Association 297(17):1946. Trumbo, P., and K. Ellwood. 2009. Developing a framework for biomarker qualification for chronic disease. Paper presented at Committee on qualification of biomarkers and surrogate endpoints in chronic disease, Washington, DC. Varmus, H. 2010. Ten years on—The human genome and medicine. New England Journal of Medicine 362(21):2028–2029. Wagner, J. A. 2002. Overview of biomarkers and surrogate endpoints in drug development. Disease Markers 18(2):41–46. Wang, T. J., P. Gona, M. G. Larson, G. H. Tofler, D. Levy, C. Newton-Cheh, P. F. Jacques, N. Rifai, J. Selhub, S. J. Robins, E. J. Benjamin, R. B. D’Agostino, and R. S. Vasan. 2006. Multiple biomarkers for the prediction of first major cardiovascular events and death. New England Journal of Medicine 355(25):2631–2639. Yetley, E. A., C. M. Pfeiffer, R. L. Schleicher, K. W. Phinney, D. A. Lacher, S. Christakos, J. H. Eckfeldt, J. C. Fleet, G. Howard, A. N. Hoofnagle, S. L. Hui, G. L. Lensmeyer, J. Massaro, M. Peacock, B. Rosner, D. Wiebe, R. L. Bailey, P. M. Coates, A. C. Looker, C. Sempos, C. L. Johnson, and M. F. Picciano. 2010. NHANES monitoring of serum 25-hydroxy- vitamin D: A roundtable summary. Journal of Nutrition 140(11):2030S–2045S.